These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37242793)

  • 1. Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population.
    Lim A; Sharma P; Stepanov O; Reddy VP
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy.
    Gill KL; Jones HM
    AAPS J; 2022 Jun; 24(4):72. PubMed ID: 35650328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents.
    Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M
    AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague.
    Nguyen D; Shaik JS; Tai G; Tiffany C; Perry C; Dumont E; Gardiner D; Barth A; Singh R; Hossain M
    Br J Clin Pharmacol; 2022 Feb; 88(2):416-428. PubMed ID: 34289143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.
    Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN
    AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.
    Chang HP; Shakhnovich V; Frymoyer A; Funk RS; Becker ML; Park KT; Shah DK
    Br J Clin Pharmacol; 2022 Jan; 88(1):290-302. PubMed ID: 34189743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
    Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.
    Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C
    Front Pharmacol; 2020; 11():868. PubMed ID: 32595502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.
    Willmann S; Thelen K; Kubitza D; Lensing AWA; Frede M; Coboeken K; Stampfuss J; Burghaus R; Mück W; Lippert J
    Thromb J; 2018; 16():32. PubMed ID: 30534008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.
    Machado TR; Honorio T; Souza Domingos TF; Candido de Paula DDS; Cabral LM; Rodrigues CR; Abrahim-Vieira BA; Teles de Souza AM
    Br J Clin Pharmacol; 2023 Oct; 89(10):3175-3194. PubMed ID: 37293836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.
    Vogt W
    Clin Pharmacokinet; 2014 Jan; 53(1):51-72. PubMed ID: 23839530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.
    Feng S; Shi J; Parrott N; Hu P; Weber C; Martin-Facklam M; Saito T; Peck R
    Clin Pharmacokinet; 2016 Jul; 55(7):823-832. PubMed ID: 26715215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.
    Peigné S; Bouzom F; Brendel K; Gesson C; Fouliard S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):13-27. PubMed ID: 26563503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach.
    Michelet R; Bindellini D; Melin J; Neumann U; Blankenstein O; Huisinga W; Johnson TN; Whitaker MJ; Ross R; Kloft C
    Front Pharmacol; 2022; 13():1090554. PubMed ID: 36712688
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
    Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
    Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-based PK/PD modelling of therapeutic macromolecules.
    Thygesen P; Macheras P; Van Peer A
    Pharm Res; 2009 Dec; 26(12):2543-50. PubMed ID: 19847627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.